Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||EAI045 + Osimertinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|EAI045||EAI-045|EAI 045||EGFR Inhibitor 4th gen 13||EAI045 is a 4th generation, allosteric, non-ATP competitive inhibitor of epidermal growth factor receptor (EGFR) with selective activity against EGFR L858R/T790M and C797S, which when combined with anti-EGFR antibodies may lead to growth inhibition in tumors harboring EGFR T790M or C797S (PMID: 27251290, PMID: 27840244, PMID: 32666476).|
|Osimertinib||Tagrisso||AZD9291||EGFR Inhibitor 3rd gen 26||Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (PMID: 29151359). Tagrisso (osimertinib) is FDA-approved for use as adjuvant therapy after resection in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or L858R, as first-line therapy in patients with metastatic NSCLC harboring EGFR exon 19 deletion or L858R, and for treatment in patients with metastatic NSCLC harboring EGFR T790M whose disease progressed after EGFR TKI therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|